乳腺浸润性导管癌中HPV18、HPV16感染的研究  

HPV18 and HPV16 infection in mammary invasive ductal carcinomas

作　　者：周晓燕[1] 朱伟萍[1] 金爱萍[1] 施达仁[1] 

机构地区：[1]复旦大学医学院附属肿瘤医院分子病理学研究室,上海200032

出　　处：《临床与实验病理学杂志》2002年第4期374-377,共4页Chinese Journal of Clinical and Experimental Pathology

摘　　要：目的 :了解乳腺浸润性导管癌中HPV18、HPV16的感染情况 ,分析其是否是乳腺癌发生的危险因素及与临床病理的相关性。方法 :根据HPV16、HPV18的DNA序列 ,合成相应特异的寡核苷酸片段 ,用加尾标记法制备地高辛标记探针 ,用原位杂交法检测 5 1例乳腺浸润性导管癌、10例相应正常乳腺上皮及 15例良性乳腺病变中HPV18、HPV16的感染 ,并分析其与患者发病年龄、肿块大小及淋巴结转移的相关性。结果 :浸润性导管癌中HPV18或 16的总阳性率达 70 6 % ,其中HPV18与HPV16的阳性率分别为 5 8 8%、4 5 1% ,均明显高于正常乳腺上皮的感染率 (30 0 %、10 0 % ;P <0 0 5 ) ;乳腺良性病变的HPV18、16阳性率分别是 6 0 0 %、6 0 % ,其中HPV18的阳性率亦显著高于正常乳腺上皮 (P <0 0 5 )。结论 :(1)HPV16和18可能是乳腺浸润性导管癌发生的致病因子 ,HPV18尚可能与乳腺良性病变的发生有关。 (2 )HPV的感染与患者年龄、肿块大小及淋巴结转移无相关性。Purpose To detect human papillomavirus 18 (HPV18) and papillomavirus 16 (HPV16) infection in mammary invasive ductal carcinomas and to analyze whether there is a risk factor in the pathogenesis of breast carcinoma and its clinical pathologic correlation. Methods HPV18 and HPV16 specific oligonucleotides were synthesized and labeled by DIG oligonucleotide tailing kit. HPV18 and HPV16 were detected by in situ hybridization in 51 cases of invasive duct carcinomas, 10 corresponding normal breast tissues and 15 benign breast lesions. The correlation between HPV infection with age, tumor size and metastasis were analyzed. Results The total positive rate of HPV18 and HPV16 in the mammary invasive duct carcinoma were 58 8% and 45 0% respectively, which were significantly higher than those in normal breast epithelium (30 0% and 10 0%) ( P <0 05). HPV18 and HPV 16 positive rates in benign breast lesions were 60 0% and 6 0% respectively, in which HPV18 was significantly higher than that in normal breast epithelium ( P <0 05). Conclusions HPV18 and HPV16 may be pathogenic factors of mammary invasive ductal carcinomas, and the former may be also related to benign breast lesions. HPV infection has no correlation with age, tumor size and metastasis.

关 键 词：乳腺浸润性导管癌 HPV18 HPV16 乳腺肿瘤 导管癌 人乳头瘤病毒 原位杂交 

分 类 号：R737.9[医药卫生—肿瘤]